Used as a neutral, historical comparison for Spruce's potential. Catalyst also acquired a drug from BioMarin and saw its market cap grow significantly to $2.5 billion, illustrating the potential of the business model.

Used as a positive historical comparison for Spruce Biosciences, as it became a multi-billion dollar company after acquiring an asset from a larger firm in a similar situation.